Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANZYGA in Pediatric CIDP
NCT04929236Phase 3Recruiting
- Sponsor
- Octapharma
- Start
- Oct 2023
- Primary completion
- Dec 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by Octapharma. Started Oct 2023; status: recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT04929236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04929236.